These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 786354)

  • 21. Antihypertensive effects of tolamolol.
    Vlachakis ND; Mendlowitz M; Krakoff LR
    Clin Pharmacol Ther; 1977 Jan; 21(1):9-15. PubMed ID: 318950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and concentration--effect relationships of bevantolol (CI-775) in normal volunteers.
    McNeil JJ; Drummer OH; Anderson AI; Louis WJ
    J Cardiovasc Pharmacol; 1986; 8(6):1201-7. PubMed ID: 2434747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical trial of the beta-adrenoreceptor-blocking agent tolamolol with the use of 24 hour blood pressure recordings.
    West MJ; Sleight P; Honour AJ
    Clin Sci Mol Med Suppl; 1976 Dec; 3():545s-547s. PubMed ID: 1071677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma levels and pharmacological effects of metoprolol administered as controlled release (Durules) and ordinary tablets in healthy volunteers.
    Johnsson G; Jordö L; Lundborg P; Regårdh CG; Rönn O
    Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):292-7. PubMed ID: 7000717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Observations on the efficacy and pharmacokinetics of sotalol after oral administration.
    Brown HC; Carruthers SG; Kelly JG; McDevitt DG; Shanks RG
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):367-72. PubMed ID: 971701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The effects of tolamolol on excito-conduction in men (author's transl)].
    Alboni P; Malacarne C; Tomasi AM; Masoni A
    G Ital Cardiol; 1977; 7(9):862-9. PubMed ID: 336446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.
    Jordö L; Attman PO; Aurell M; Johansson L; Johnsson G; Regårdh CG
    Clin Pharmacokinet; 1980; 5(2):169-80. PubMed ID: 6102500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical pharmacologic observations on timolol. I. Disposition and effect in relation to plasma level in normal individuals.
    Ishizaki T; Tawara K; Oyama Y; Nakaya H
    J Clin Pharmacol; 1978; 18(11-12):511-8. PubMed ID: 721948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality].
    Balant L; Gorgia A; Tschopp JM; Revillard C; Fabre J
    Schweiz Med Wochenschr; 1976 Oct; 106(41):1403-7. PubMed ID: 12563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of bunitrolol on heart rate, metabolic parameters during physical exercise, and performance].
    Keul J; Lehmann M; Wybitul K
    Arzneimittelforschung; 1981; 31(11):1948-53. PubMed ID: 6119096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of beta-blocking activity of trimepranol in man.
    Pentikäinen PJ; Neuvonen PJ; Penttilä A
    Int J Clin Pharmacol Biopharm; 1978 Jun; 16(6):279-84. PubMed ID: 27464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment.
    Bengtsson C; Johnsson G; Regårdh CG
    Clin Pharmacol Ther; 1975 Apr; 17(4):400-8. PubMed ID: 235398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug.
    Conway FJ; Fitzgerald JD; McAinsh J; Rowlands DJ; Simpson WT
    Br J Clin Pharmacol; 1976 Apr; 3(2):267-72. PubMed ID: 973955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses.
    Regårdh CG; Johnsson G; Jordö L; Sölvell L
    Acta Pharmacol Toxicol (Copenh); 1975; 36(Suppl 5):45-58. PubMed ID: 1079687
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of tolamolol versus propranolol on cardiovascular haemodynamics in patients with angina.
    Aronow WS; March H; Vangrow JS; Cassidy J; Kern JC; Khemka M; Vawter M; Pagano J
    Br Heart J; 1974 Nov; 36(11):1078-81. PubMed ID: 4155953
    [No Abstract]   [Full Text] [Related]  

  • 36. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human pharmacology of the methamphetamine stereoisomers.
    Mendelson J; Uemura N; Harris D; Nath RP; Fernandez E; Jacob P; Everhart ET; Jones RT
    Clin Pharmacol Ther; 2006 Oct; 80(4):403-20. PubMed ID: 17015058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of a new cardioselective beta-adrenergic blocker (tolamolol) on exercise tolerance in patients with angina pectoris.
    Sood NK; Havard CW
    Thorax; 1973 May; 28(3):331-4. PubMed ID: 4146782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The electrophysiologic effects of tolamolol (UK-6558-01) on the passive membrane properties of mammalian cardiac Purkinje fibers.
    Arnsdorf MF; Friedlander I
    J Pharmacol Exp Ther; 1976 Dec; 199(3):601-10. PubMed ID: 1036501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic parameters of terbutaline in healthy man. An overview.
    Nyberg L
    Eur J Respir Dis Suppl; 1984; 134():149-60. PubMed ID: 6586475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.